A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT).

Trial Profile

A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of 2 g per day of strontium ranelate versus marketed bisphosphonates in women with postmenopausal osteoporosis on bone microarchitecture as measured by high-resolution peripheral-quantitative computed tomography (p-QCT).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Strontium ranelate (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
    • 10 Dec 2010 Company (Institut de Recherches Internationales Servier) added in association field as reported by ISRCTN: Current Controlled Trials.
    • 01 Aug 2010 Results have been published in Rheumatology International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top